Brown Douglas Matthew
Known title: Chief Strategy OfficerCIK: 0001849414
Associated companies
Transaction History
| NEO | ▲ Buy | Grant | 82,305 | $0 | 4/1/2022 | View on chart |
| NEO | ▼ Sell | Tax Withholding | 867 | $0 | 3/2/2022 | View on chart |
| NEO | ▲ Buy | Grant | 35,030 | $0 | 3/1/2022 | View on chart |
| NEO | ▲ Buy | Grant | 30,572 | $0 | 12/30/2021 | View on chart |
| NEO | ▼ Sell | Open Market | 33,334 | $1.2M | 11/26/2021 | View on chart |
| NEO | ▼ Sell | Open Market | 33,333 | $1.2M | 11/24/2021 | View on chart |
| NEO | ▼ Sell | Open Market | 33,333 | $1.2M | 11/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.